HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leiner Health Products’ reorganization

This article was originally published in The Tan Sheet

Executive Summary

OTC drug, dietary supplement private labeler's reorganization plan approved by Wilmington, Del. bankruptcy Judge Peter Walsh April 15. Prepackaged Chapter 11 filing, which previously received senior bank lender and bondholder approval, calls for restructuring current bank debt into two term loans totaling approximately $243 mil., plus a $20 mil. revolving credit facility. Senior subordinated note holders will receive $15 mil. cash and newly issued preferred stock in exchange for the notes (1"The Tan Sheet" March 11, 2000, p. 6)...

You may also be interested in...

Leiner Reorganization Plan Confirmation Hearing Slated For April

An April 15 hearing is scheduled for confirmation of Leiner Health Products' reorganization plan, filed Feb. 28 in Wilmington, Del. bankruptcy court

UK OTC Industry Association Elects Haleon’s Bas Vorsteveld As President

Haleon’s UK and Ireland general manager Bas Vorsteveld becomes PAGB president, replacing Perrigo's Neil Lister. Lister reflects on a turbulent four years chairing the UK industry association. 

Countries To Discuss Pandemic Treaty Next Year Amid Industry Concern

A World Health Organization negotiating body has agreed to develop a “zero draft” of the proposed pandemic treaty for discussion at a meeting of WHO member states in February next year. But the international pharmaceutical industry has reiterated its concerns about some of the proposals being put forward.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts